Molecular testing (e.g., FISH, reverse transcription PCR, or next-generation sequencing) can readily identify PAX/FOXO1 fusions, and because results may impact treatment decisions, it was recommended by these sarcoma experts to test for FOXO1 fusions on all patients with alveolar or embryonal histology. This evidence concerns the gene FOXO1 and sarcoma.